RT @RichardPAConway: Almayali et al. Follow-up of GLORIA study. Now tapering of the pred 5mg after 2 years. Small increa

Tweet Author

Tweet Content

Almayali et al. Follow-up of GLORIA study. Now tapering of the pred 5mg after 2 years. Small increase in disease activity (to same level as prev placebo), numerical increase in flare. No adrenal insufficiency @RheumNow #ACR22 Abstr#2000 https://t.co/5oclSdlXWA https://t.co/HT2pmsxPiC

Links

Tapering of Long-term, Low Dose Glucocorticoids in Senior Rheumatoid Arthritis … https://acrabstracts.org/abstract/tapering-of-long-term-low-dose-glucocorticoid…

RT @RichardPAConway: Wow! Walrabenstein et al. RCT of plant-based diet (and exercise and stress management) vs usual car

Tweet Author

RichardPAConway

Tweet Content

Wow! Walrabenstein et al. RCT of plant-based diet (and exercise and stress management) vs usual care in low-moderate disease activity RA. It worked! But which of the 3 parts of the intervention was responsible? @RheumNow #ACR22 Abstr#1998 https://t.co/X1f07ZWPjU https://t.co/nkM4misfFW

Links

Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical … https://acrabstracts.org/abstract/effect-of-a-lifestyle-program-based-on-a-whol…

RT @RichardPAConway: Yokose et al. Higher risk of mortality in women with gout. Primarily CVD related death. @RheumNow #

Tweet Author

RichardPAConway

Tweet Content

Yokose et al. Higher risk of mortality in women with gout. Primarily CVD related death. @RheumNow #ACR22 Abstr#1757 https://t.co/Ft3Km8Jw17 https://t.co/uBOUnV4n0Z

Links

The Independent Impact of Gout on Mortality and Risk of Coronary Heart Disease … https://acrabstracts.org/abstract/the-independent-impact-of-gout-on-mortality-a…

RT @RichardPAConway: Haibel et al. Intraarticular morphine no different to placebo and inferior to steroid in knee OA. @

Tweet Author

RichardPAConway

Tweet Content

Haibel et al. Intraarticular morphine no different to placebo and inferior to steroid in knee OA. @RheumNow #ACR22 Abstr#1833 https://t.co/9dOlfYMVlj https://t.co/a3uvw3gVw3

Links

Intraarticular Morphine in Knee-arthritis – Results of a Randomized Placebo-con… https://acrabstracts.org/abstract/intraarticular-morphine-in-knee-arthritis-res…

RT @RichardPAConway: Kivitz et al. Phase 2 RCT Dazodalibep (non-antibody biologic antagonist of CD40L) in csDMARD/bDMARD

Tweet Author

RichardPAConway

Tweet Content

Kivitz et al. Phase 2 RCT Dazodalibep (non-antibody biologic antagonist of CD40L) in csDMARD/bDMARD-IR RA. Improve DAS28-CRP, CDAI, SDAI, TJC, SJC at day 113. @RheumNow #ACR22 Abstr#2008 https://t.co/RwRbeFC4rt https://t.co/F8bEI1lZGM

Links

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight an… https://acrabstracts.org/abstract/a-phase-2-randomized-double-blind-placebo-con…

RT @ericdeinmd: L09 #ACR22 MTX in Post-Roe Era 6% patients reported barrier to MTX access 1 pt noted restriction to HCQ

Tweet Author

ericdeinmd

Tweet Content

L09 #ACR22 MTX in Post-Roe Era 6% patients reported barrier to MTX access 1 pt noted restriction to HCQ Most delays due to pharmacy - told due to pregnancy/abortion concerns or unexplained reason Rare BUT Real Problem - shows importance of @ACRheumDC advocacy efforts @RheumNow https://t.co/8Yr7nynzN6

RT @ericdeinmd: L10 #ACR22 Efgartigimod in IMNM IgG1 Fc fragment targeting neonatal Fc receptor (FcRn) Restored grip and

Tweet Author

ericdeinmd

Tweet Content

L10 #ACR22 Efgartigimod in IMNM IgG1 Fc fragment targeting neonatal Fc receptor (FcRn) Restored grip and muscle strength in mice studies with pathogenic anti-HMGCR+ (p<0.05) Total IgG and anti-HMGCR Ab became undetectable @RheumNow

14 November 2022

Is exercise the missing medicine in lupus?

For lupus, sedentary lifestyle may be a driving force of disease activity. Today, the final day of ACR, Sarah Patterson, MD from UCSF will present oral abstract #2225 entitled “Physical Inactivity is Associated with Increased Expression of T cell inflammatory genes in Systemic Lupus.”

RT @RichardPAConway: Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-an

Tweet Author

RichardPAConway

Tweet Content

Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-analysis of CARES trial. @RheumNow #ACR22 Abstr#1809 https://t.co/I6evAl4BLd https://t.co/n70FvYah1p

Links

Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients:… https://acrabstracts.org/abstract/impact-of-colchicine-prophylaxis-on-cardiovas…

RT @RichardPAConway: Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, R

Tweet Author

RichardPAConway

Tweet Content

Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, Rate ratio vs TNFi 2.2 (1.4-3.2). Age-adjusted HR 1.6 (1.0-2.6) @RheumNow #ACR22 Abstr#1752 https://t.co/PvBq2O9qPv https://t.co/XBfistBMhW

Links

Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic a… https://acrabstracts.org/abstract/cancer-risk-in-patients-with-rheumatic-diseas…

Topics

RT @RichardPAConway: Almayali et al. Follow-up of GLORIA study. Now tapering of the pred 5mg after 2 years. Small increa

RT @RichardPAConway: Wow! Walrabenstein et al. RCT of plant-based diet (and exercise and stress management) vs usual car

RT @RichardPAConway: Yokose et al. Higher risk of mortality in women with gout. Primarily CVD related death. @RheumNow #

RT @RichardPAConway: Haibel et al. Intraarticular morphine no different to placebo and inferior to steroid in knee OA. @

RT @RichardPAConway: Kivitz et al. Phase 2 RCT Dazodalibep (non-antibody biologic antagonist of CD40L) in csDMARD/bDMARD

RT @ericdeinmd: L09 #ACR22 MTX in Post-Roe Era 6% patients reported barrier to MTX access 1 pt noted restriction to HCQ

RT @ericdeinmd: L10 #ACR22 Efgartigimod in IMNM IgG1 Fc fragment targeting neonatal Fc receptor (FcRn) Restored grip and

RT @RichardPAConway: Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-an

RT @RichardPAConway: Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, R

Do you get our email newsletter?